Lyell Immunopharma issues colorectal cancer drug safety update

on Lyell Immunopharma Inc. (NASDAQ: LYEL) stock is up on Monday as the company is providing an update on the safety profile ...
MSN on MSN

RNAZ: Introducing RNA therapeutics

By John Vandermosten, CFA NASDAQ: RNAZ READ THE FULL RNAZ RESEARCH NOTE RNA Oncology Ribonucleic acid (RNA) oncology is a specialized field in the cancer space that focuses on using RNA-based ...

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, today announced it will host its first live ...

TransCode annonce que son essai de phase 1a sur le cancer a atteint ses objectifs de sécurité et fait passer le candidat-médicament en phase 2a

TransCode Therapeutics a déclaré mercredi que son essai de phase 1a d'escalade de dose pour sa thérapie anticancéreuse TTX-MC138 a atteint son critère d'évaluation principal en matière ...

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of ...

Compliance Advocates Corp.

Compliance Advocates Corp. research and ratings by Barron's. View CODV revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of ...
Morningstar

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today ...

TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
Morningstar

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced ...

TransCode Therapeutics Delays 2025 Annual Filing

Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
MarketWatch

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

The MarketWatch News Department was not involved in the creation of this content. BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage ...